ArriVent BioPharma Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 12, 2025
NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent Company progress.
Read more at globenewswire.com
